Figure 5.

modVEGF-treated iPSC-CMs retain proliferation capacity following transplantation in infarcted rat hearts

(A and B) Comparison of Ki67 immunostainings of engrafted CMs from MI-iPSC-CMs^modLuc (A) or MI-iPSC-CMs^modVEGF (B) 1 week post transplantation: red, cTnT; green, Ki67; blue, DAPI. (C) Representative confocal immunostaining of cTnT and Ki67 double-positive cells in the MI-iPSC-CMs^modVEGF group at 4 weeks post transplantation. The white arrows indicate nuclear presence of Ki67. (A–C), Scale bars: 75 μm. Scale bars (zoomed snapshot), 25 μm. (D) Quantitative analysis and comparison of Ki67 positive cells at 1 and 4 weeks between the MI-iPSC-CMs^modLuc group and MI-iPSC-CMs^modVEGF group. (E–H) Comparison of Ki67 immunostainings of host myocardial tissue following administration of MI (E) or MI-iPSC-CMs^modLuc (F) or MI-iPSC-CMs^modVEGF (G) 1 week post transplantation: green, cTnT; red, Ki67; blue, DAPI. (H) Representative confocal immunostaining of cTnT and Ki67 double-positive cells in the MI-iPSC-CMs^modVEGF group at 4 weeks post transplantation. The white arrows indicate nuclear presence of cTnT and Ki67 double-positive cells. (E–H) Scale bars, 25μm. 1 week, MI-iPSC-CMs^modLuc n = 3, MI-iPSC-CMs^modVEGF n = 3; 4 weeks, MI-iPSC-CMs^modLuc n = 7, MI-iPSC-CMs^modVEGF n = 5. All data are means ± SD. ND, not detected; ∗p < 0.05, ∗∗p < 0.01.